104 related articles for article (PubMed ID: 35961931)
1. Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenocarcinoma.
Elshami M; Ahmed FA; Kakish H; Hue JJ; Hoehn RS; Rothermel LD; Bajor D; Mohamed A; Selfridge JE; Ammori JB; Hardacre JM; Winter JM; Ocuin LM
HPB (Oxford); 2022 Nov; 24(11):1878-1887. PubMed ID: 35961931
[TBL] [Abstract][Full Text] [Related]
2. Average treatment effect of facility hepatopancreatobiliary malignancy case volume on survival of patients with nonoperatively managed hepatobiliary malignancies.
Elshami M; Ahmed FA; Hue JJ; Kakish H; Hoehn RS; Rothermel LD; Bajor D; Mohamed A; Selfridge JE; Ammori JB; Hardacre JM; Winter JM; Ocuin LM
Surgery; 2023 Feb; 173(2):289-298. PubMed ID: 36402613
[TBL] [Abstract][Full Text] [Related]
3. A nationwide analysis of clinical trial participation for common hepato-pancreato-biliary malignancies demonstrates survival advantages for subsets of trial patients but disparities in and infrequency of enrollment.
Elshami M; Hue JJ; Hoehn RS; Rothermel LD; Bajor D; Mohamed A; Selfridge JE; Chavin KD; Ammori JB; Hardacre JM; Winter JM; Ocuin LM
HPB (Oxford); 2022 Aug; 24(8):1280-1290. PubMed ID: 35063353
[TBL] [Abstract][Full Text] [Related]
4. Trends and disparities in the utilization of systemic chemotherapy in patients with metastatic hepato-pancreato-biliary cancers.
Elshami M; Ahmed FA; Kakish H; Hue JJ; Hoehn RS; Rothermel LD; Bajor D; Mohamed A; Selfridge JE; Ammori JB; Hardacre JM; Winter JM; Ocuin LM
HPB (Oxford); 2023 Feb; 25(2):239-251. PubMed ID: 36411233
[TBL] [Abstract][Full Text] [Related]
5. Intensity-modulated radiotherapy at high-volume centers improves survival in patients with esophageal adenocarcinoma receiving trimodality therapy.
Yang GQ; Mhaskar R; Rishi A; Naghavi AO; Frakes JM; Almhanna K; Fontaine J; Pimiento JM; Hoffe SE
Dis Esophagus; 2019 Aug; 32(8):. PubMed ID: 30597022
[TBL] [Abstract][Full Text] [Related]
6. Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy.
Barzi A; Lara PN; Tsao-Wei D; Yang D; Gill IS; Daneshmand S; Klein EA; Pinski JK; Penson DF; Quinn DI; Sadeghi S
Cancer; 2019 Nov; 125(21):3853-3863. PubMed ID: 31398279
[TBL] [Abstract][Full Text] [Related]
7. Incidence and comparative outcomes of periampullary cancer: A population-based analysis demonstrating improved outcomes and increased use of adjuvant therapy from 2004 to 2012.
Hester CA; Dogeas E; Augustine MM; Mansour JC; Polanco PM; Porembka MR; Wang SC; Zeh HJ; Yopp AC
J Surg Oncol; 2019 Mar; 119(3):303-317. PubMed ID: 30561818
[TBL] [Abstract][Full Text] [Related]
8. An Age-Stratified Analysis of Early Postoperative Mortality Among Medicare-Eligible Patients With Common Gastrointestinal and Hepato-pancreato-biliary Malignancies.
Loftus AW; Hue JJ; Elshami M; Miller-Ocuin JL; Steinhagen E; Hoehn RS; Rothermel LD; Ammori JB; Hardacre JM; Ocuin LM
Am Surg; 2024 Jun; ():31348241256057. PubMed ID: 38839096
[No Abstract] [Full Text] [Related]
9. Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base.
Rutter CE; Park HS; Corso CD; Lester-Coll NH; Mancini BR; Yeboa DN; Johung KL
Cancer; 2015 Dec; 121(23):4141-9. PubMed ID: 26280559
[TBL] [Abstract][Full Text] [Related]
10. Duration of chemotherapy prior to chemoradiation affects survival outcomes for resected stage I-II or unresected stage III pancreatic cancer.
Ma SJ; Iovoli AJ; Hermann GM; Prezzano KM; Singh AK
Cancer Med; 2019 Aug; 8(9):4110-4123. PubMed ID: 31183965
[TBL] [Abstract][Full Text] [Related]
11. Treatment and survival of patients with pancreatic ductal adenocarcinoma: 15-year national cohort.
Nymo LS; Myklebust TÅ; Hamre H; Møller B; Lassen K
BJS Open; 2022 Mar; 6(2):. PubMed ID: 35257140
[TBL] [Abstract][Full Text] [Related]
12. Artificial neural networks for multi-omics classifications of hepato-pancreato-biliary cancers: towards the clinical application of genetic data.
Bagante F; Spolverato G; Ruzzenente A; Luchini C; Tsilimigras DI; Campagnaro T; Conci S; Corbo V; Scarpa A; Guglielmi A; Pawlik TM
Eur J Cancer; 2021 May; 148():348-358. PubMed ID: 33774439
[TBL] [Abstract][Full Text] [Related]
13. Risk of hepato-pancreato-biliary cancer is increased by primary sclerosing cholangitis in patients with inflammatory bowel disease: A population-based cohort study.
Yu J; Refsum E; Helsingen LM; Folseraas T; Ploner A; Wieszczy P; Barua I; Jodal HC; Melum E; Løberg M; Blom J; Bretthauer M; Adami HO; Kalager M; Ye W
United European Gastroenterol J; 2022 Mar; 10(2):212-224. PubMed ID: 35107865
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Hospital Volume and Risk-Standardized Mortality Rate as a Proxy for Hospital Quality in Complex Oncologic Hepatopancreatobiliary Surgery.
Julian WT; Elshami M; Ammori JB; Hardacre JM; Ocuin LM
Ann Surg Oncol; 2024 May; ():. PubMed ID: 38700800
[TBL] [Abstract][Full Text] [Related]
15. External radiation is associated with limited improvement in overall survival in resected margin-negative stage IIB pancreatic adenocarcinoma.
Kantor O; Talamonti MS; Lutfi W; Wang CH; Winchester DJ; Marsh R; Prinz RA; Baker MS
Surgery; 2016 Dec; 160(6):1466-1476. PubMed ID: 27614417
[TBL] [Abstract][Full Text] [Related]
16. The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who received definitive surgery of the pancreatic tumor: a retrospective analysis of the National Cancer Database.
Amin S; Baine M; Meza J; Alam M; Lin C
Radiat Oncol; 2020 Jun; 15(1):139. PubMed ID: 32493354
[TBL] [Abstract][Full Text] [Related]
17. Association of Timing of Adjuvant Therapy With Survival in Patients With Resected Stage I to II Pancreatic Cancer.
Ma SJ; Oladeru OT; Miccio JA; Iovoli AJ; Hermann GM; Singh AK
JAMA Netw Open; 2019 Aug; 2(8):e199126. PubMed ID: 31411712
[TBL] [Abstract][Full Text] [Related]
18. Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodenectomy.
Hue JJ; Sugumar K; Markt SC; Hardacre JM; Ammori JB; Rothermel LD; Winter JM; Ocuin LM
Surgery; 2021 Jul; 170(1):207-214. PubMed ID: 33454134
[TBL] [Abstract][Full Text] [Related]
19. The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era.
Chen YW; Ornstein MC; Wood LS; Allman KD; Martin A; Beach J; Gilligan T; Garcia JA; Rini BI
Urol Oncol; 2018 Oct; 36(10):470.e19-470.e29. PubMed ID: 30131292
[TBL] [Abstract][Full Text] [Related]
20. A matched-cohort analysis of 192 pancreatic anaplastic carcinomas and 960 pancreatic adenocarcinomas: A 13-year North American experience using the National Cancer Data Base (NCDB).
Paniccia A; Hosokawa PW; Schulick RD; Henderson W; Kaplan J; Gajdos C
Surgery; 2016 Aug; 160(2):281-92. PubMed ID: 27085687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
